View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 10, 2020

Medtronic receives FDA approval for feasibility study of TTVR system

Medtronic has received the US Food and Drug Administration (FDA) approval for the early feasibility study (EFS) of the Intrepid Transcatheter Tricuspid Valve Replacement (TTVR) system in patients with severe, symptomatic tricuspid regurgitation.

Medtronic has received the US Food and Drug Administration (FDA) approval for the early feasibility study (EFS) of the Intrepid Transcatheter Tricuspid Valve Replacement (TTVR) system in patients with severe, symptomatic tricuspid regurgitation.

Free Report
img

Find the right pricing strategy for your medical device

How do your competitors set prices in different markets? Will reducing your prices win market share from your main competitors? Do you need to position products differently for different markets? To find out, use our Global Brand Pricing tool to achieve optimal pricing for your devices. Detect price changes, understand competitor market positioning, and plan new product launches, by accessing this tool today. It features:
  • A proprietary algorithm that leverages numerous pricing sources, with an emphasis on real-world data
  • Estimates of the likely spread of selling prices per brand and manufacturer, as well as 3-year forecasts for prices
  • Medical device pricing data that can be tracked by market, company, and brand
  • Additional categories that can be built on a custom basis
Use our tool to access competitor pricing strategies across multiple geographies, and various dynamic case studies from the likes of Germany and China, to benchmark yourself against your competitors and future proof your pricing strategies.
by GlobalData
Enter your details here to receive your free Report.

The approval follows the receipt of FDA breakthrough device designation for the Intrepid TTVR System, which is currently an investigational device across the world.

Tricuspid regurgitation is estimated to affect over two million patients in the US. The condition is caused when the diseased, damaged or malfunctioning tricuspid valve allows blood to flow back into the heart’s upper right chamber and may lead to eventual heart failure or death.

It is a highly undertreated disease due to the morbidity and mortality related to surgical intervention.

Co-principal investigator of the study and Minneapolis Heart Institute cardiothoracic surgery chief Vinayak Bapat said: “The clinical experience generated during this initial study phase will be critical for the future of the therapy as many of these patients are not good candidates for traditional surgical tricuspid valve interventions due to their poor right heart functions and are higher risk due to co-morbidities.”

Medtronic noted that the Intrepid transcatheter valve is also being assessed for the treatment of symptomatic mitral valve regurgitation in the transfemoral mitral early feasibility study.

The device is implanted using a transfemoral delivery catheter, which helps physicians to deliver and position the valve through a catheter inserted in the femoral vein.

Earlier this month, the US FDA approved Medtronic’s MiniMed 770G System for use by paediatric patients aged between two and six years with type 1 diabetes.

Last month, the company started the post-market study of the InterStim Micro System for sacral neuromodulation (SNM) therapy to treat overactive bladder (OAB), faecal incontinence (FI) and non-obstructive urinary retention (NOUR).

Related Companies

Free Report
img

Find the right pricing strategy for your medical device

How do your competitors set prices in different markets? Will reducing your prices win market share from your main competitors? Do you need to position products differently for different markets? To find out, use our Global Brand Pricing tool to achieve optimal pricing for your devices. Detect price changes, understand competitor market positioning, and plan new product launches, by accessing this tool today. It features:
  • A proprietary algorithm that leverages numerous pricing sources, with an emphasis on real-world data
  • Estimates of the likely spread of selling prices per brand and manufacturer, as well as 3-year forecasts for prices
  • Medical device pricing data that can be tracked by market, company, and brand
  • Additional categories that can be built on a custom basis
Use our tool to access competitor pricing strategies across multiple geographies, and various dynamic case studies from the likes of Germany and China, to benchmark yourself against your competitors and future proof your pricing strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network